IN10018 plus targeted therapy for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called IN10018 combined with a targeted therapy (third-generation EGFR-TKI) for people with advanced EGFR-mutant non-small cell lung cancer. It's designed for different stages of treatment, from first-time therapy to after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and willing to sign a consent form.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation.
- Your cancer has a specific EGFR mutation (Ex19del or L858R).
- You are in one of three groups: currently taking Furmonertinib as first treatment, have already tried a third-generation EGFR-TKI and chemotherapy, or have never had any cancer treatment for your advanced NSCLC.
- You are able to do light work or are fully active (ECOG 0 or 1) and expected to live more than 3 months.
- You do not have certain other untreated conditions like active brain metastases, severe heart or lung disease, or an allergy to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
This trial tests giving a targeted drug (furmonertinib) combined with other treatments before surgery for lung cancer with an EGFR mutation. The goal is to shrink the tumor and make surgery more effective.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.